Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 03, 2019 08:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Present at the 9th Annual LD Micro Invitational

BEDMINSTER, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief...
May 28, 2019 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Publication of MAT2203 Preclinical Cryptococcal Meningitis Data in the American Society for Microbiology Journal, mBio

– Efficacy of oral delivery of amphotericin B (MAT2203) demonstrated comparable efficacy to IV amphotericin, with similar survival of animals and reduction in fungal burden – – Cryptococcal...
May 21, 2019 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces Abstract Accepted for Presentation at ASM Microbe 2019

BEDMINSTER, N.J., May 21, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that its abstract of preclinical...
May 15, 2019 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Announces a Research Collaboration with ViiV Healthcare to Evaluate Formulation of Antiviral Drug Candidates

BEDMINSTER, N.J., May 15, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that they have entered into a research collaboration with ViiV Healthcare, a...
May 14, 2019 07:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Provides Corporate Update and Reports First Quarter 2019 Financial Results

BEDMINSTER, N.J., May 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced its financial results for the...
May 08, 2019 08:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Host Conference Call and Webcast to Discuss First Quarter 2019 Operational and Financial Results on May 14, 2019

BEDMINSTER, N.J., May 08, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a...
May 02, 2019 08:35 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Ring NYSE Opening Bell® on May 6, 2019

BEDMINSTER, N.J., May 02, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has been invited to ring...
May 01, 2019 08:35 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Selected to Present at the BioNJ Ninth Annual BioPartnering Conference

BEDMINSTER, N.J., May 01, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that Theresa Matkovits, Ph.D.,...
April 02, 2019 07:05 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma Reports 2018 Financial Results and Provides Corporate Update

– Key focus on advancing the development of MAT9001, a potential best-in-class cardiovascular therapy in what is projected to be a new, multi-billion dollar prescription-only omega-3 market – –...
March 26, 2019 08:00 ET | Source: Matinas BioPharma Holdings, Inc.

Matinas BioPharma to Announce Full-Year 2018 Operational and Financial Results on April 2, 2019

BEDMINSTER, N.J., March 26, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a...